Literature DB >> 11091756

Multicentric Breast Carcinoma: Evaluation of Clinicopathological and Immunohistochemical Characteristics.

.   

Abstract

Multicentric breast carcinomas not diagnosed clinically, were examined by serial step-cut sectioning of the whole breast, and multicentric carcinoma cases were compared with single carcinoma cases with regard to histological and clinicopathological findings. In 7(3.7%) out of 187 surgically resected breasts, latent carcinomas apart from the main carcinoma were noted. The size of the latent carcinoma varied from 0.2 to 5 cm in diameter. The histological type was noninvasive ductal carcinoma in six cases and invasive ductal carcinoma in one case. When the main carcinoma was small in size (less than 2.5 cm in diameter), and showed papillotubular carcinoma as the histological type or had estrogen receptor (ER) by the dextran-coated charcoal (DCC) method, the incidence of latent carcinoma was high. In 5 of 6 cases with latent carcinoma examined by immunohistochemistry, latent carcinomas showed expression of ER. Concerning Ki-67, proliferating cell nuclear antigen (PCNA) and p53 protein, there was no significant difference between the main and latent carcinomas, as well as with other clinicopathological factors.

Entities:  

Year:  1996        PMID: 11091756     DOI: 10.1007/BF02966983

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  42 in total

1.  Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis.

Authors:  A A Sahin; J Ro; J Y Ro; M B Blick; A K el-Naggar; N G Ordonez; H A Fritsche; T L Smith; G N Hortobagyi; A G Ayala
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

2.  Borderline epithelial lesions of the breast.

Authors:  J Rosai
Journal:  Am J Surg Pathol       Date:  1991-03       Impact factor: 6.394

3.  Tubular carcinoma of the breast: association with multicentricity, bilaterality, and family history of mammary carcinoma.

Authors:  M D Lagios; M R Rose; F R Margolin
Journal:  Am J Clin Pathol       Date:  1980-01       Impact factor: 2.493

4.  Potential value of hormone receptor assay in carcinoma in situ of breast.

Authors:  R Barnes; S Masood
Journal:  Am J Clin Pathol       Date:  1990-11       Impact factor: 2.493

5.  Involvement of the nipple in early carcinoma of the breast.

Authors:  S Suehiro; K Inai; S Tokuoka; Y Hamada; M Toi; M Niimoto; T Hattori
Journal:  Surg Gynecol Obstet       Date:  1989-03

6.  Prognostic value of the topographic grid method in women with T2 N- breast cancer. Statistical results from a series of 203 patients.

Authors:  P Noel; F Chauvin; C Bailly; M Clavel; M Mayer; J Y Bobin; R Blondet; B Crozet; P Zlatoff; M Tcheou
Journal:  Cancer       Date:  1985-05-01       Impact factor: 6.860

7.  Maintenance of p53 alterations throughout breast cancer progression.

Authors:  A M Davidoff; B J Kerns; J D Iglehart; J R Marks
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

8.  Estrogen receptor immunohistochemistry in carcinoma in situ of the breast.

Authors:  M E Bur; M J Zimarowski; S J Schnitt; S Baker; R Lew
Journal:  Cancer       Date:  1992-03-01       Impact factor: 6.860

9.  Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.

Authors:  B Zafrani; A Leroyer; A Fourquet; M Laurent; D Trophilme; P Validire; X Sastre-Garau
Journal:  Semin Diagn Pathol       Date:  1994-08       Impact factor: 3.464

10.  Nuclear p53 immunoreaction associated with poor prognosis of breast cancer.

Authors:  K Iwaya; H Tsuda; H Hiraide; K Tamaki; S Tamakuma; T Fukutomi; K Mukai; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1991-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.